Compare ADMA Biologics Inc (ADMA) vs Amer Sports Inc (AS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Amer Sports Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Amer Sports Inc trades at $33.87 (market cap $21.04B). The key difference: Amer Sports Inc is far larger — about 9.7× ADMA Biologics Inc's market cap, and Amer Sports Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | AS | |
|---|---|---|
Market Cap | $2.18B | $21.04B |
Sector | Health | Technology |
52-Week High | $20.38 | $41.96 |
52-Week Low | $7.60 | $29.54 |
Enterprise Value | $2.25B | $21.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Amer Sports (AS) trades at $36.84, up 2.02% today, with a bullish technical signal from moving averages and strong analyst consensus. The company reported robust Q1 2026 results, beating EPS estimates with $0.38 versus $0.31 expected, and raised full-year guidance. Revenue grew 32% year-over-year to $1.95 billion, driven by strength in Arc'teryx and Salomon brands.
Outlook is positive given earnings momentum and raised 2026 guidance, but risks include high valuation (P/E 45.2) and dependence on premium brand sustainability. The consensus price target of $58.67 implies significant upside, supported by 12 buy ratings. Investors should monitor Q2 2026 earnings on August 18 for continued growth validation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Amer Sports Inc
Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, and Atomic. It designs and manufactures high-quality equipment, apparel, and footwear for athletes worldwide.
Read more on AS →
